ANKE BIO(SZ:300009) Xin Lang Cai Jing·2025-10-31 09:05Core Viewpoint - Anke Bio is a leading company in the domestic biopharmaceutical sector, focusing on cell engineering, gene engineering, and precision medicine, with strong R&D capabilities [1] Group 1: Business Performance - In Q3 2025, Anke Bio achieved a revenue of 1.963 billion yuan, ranking 7th among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The net profit for the same period was 563 million yuan, also ranking 7th, with the top performer, Tonghua Dongbao, reporting a net profit of 1.188 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Anke Bio's debt-to-asset ratio was 14.81%, lower than the previous year's 17.20% and below the industry average of 26.88%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 75.97%, slightly down from 77.75% year-on-year but still above the industry average of 70.17%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 11.15% to 73,000, while the average number of circulating A-shares held per shareholder decreased by 10.04% to 16,700 [5] Group 4: Business Highlights - The biopharmaceutical segment showed signs of recovery, with the first antibody drug, "Ansaiting," seeing a sales revenue increase of 298% [6] - Significant progress in business collaborations, including exclusive commercialization rights for recombinant human follicle-stimulating hormone-CTP fusion protein injection [6][7] - The company is advancing its innovation drug transformation with multiple projects making progress, such as the completion of Phase I clinical trials for "PA3-17 injection" [6][7]